Safety and Tolerability of Subcutaneous IgPro20 at High Infusion Parameters in Patients with Primary Immunodeficiency: Findings from the Pump-Assisted Administration Cohorts of the HILO Study

PURPOSE: To evaluate the safety and tolerability of subcutaneous IgPro20 (Hizentra(®), CSL Behring, King of Prussia, PA, USA) administered at high infusion parameters (> 25 mL and > 25 mL/h per injection site) in patients with primary immunodeficiency. METHODS: The Hizentra(®) Label Optimizati...

Descripción completa

Detalles Bibliográficos
Autores principales: Anderson, John T., Bonagura, Vincent R., Cowan, Juthaporn, Hsu, Connie, Mustafa, S. Shahzad, Patel, Niraj C., Routes, John M., Sriaroon, Panida, Vinh, Donald C., Hofmann, Jutta H., Praus, Michaela, Rojavin, Mikhail A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7858210/
https://www.ncbi.nlm.nih.gov/pubmed/33409867
http://dx.doi.org/10.1007/s10875-020-00912-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7858210/
https://www.ncbi.nlm.nih.gov/pubmed/33409867
http://dx.doi.org/10.1007/s10875-020-00912-5

Ejemplares similares